U nderstanding the mechanisms of cardiac lineage commitment is important for identifying the pathophysiological basis of congenital heart disease, the most common cause of human birth defects. In addition, a detailed understanding of cardiac lineage commitment also may be important for successful cell-based therapies. [1] [2] [3] [4] Recently, we and others have described the isolation and characterization of embryo-derived and embryonic stem cell (ESC)-derived cardiac progenitor cells (CPCs). [5] [6] [7] [8] [9] These cells give rise to a variety of different cell types in the developing heart. Although the developmental potential of embryonic CPCs is an active area of investigation, limited progress has been made in understanding the genes and pathways that regulate the commitment of multipotent mesodermal precursor cells into committed CPCs.
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Yin Yang 1 (YY1), a member of the GLI-Kruppel family of DNA-binding zinc finger transcription factor (TF), 10, 11 can activate or inhibit transcription in a context-dependent manner. 12 Global deletion of the murine YY1 alleles results in peri-implantation embryonic lethality. 13 Haploinsufficiency of a YY1 allele results in neural defect and cyanosis with subsequent fetal demise during late gestation. Mechanistically, YY1 has been described to anchor polycomb group proteins to chromatin DNA and may substitute for polycomb protein pleiohomeotic during Drosophila development. 14 The role of YY1 in postnatal skeletal and cardiac sarcomeric gene transcription has been previously examined. Binding sites for YY1 have been identified within the regulatory regions of several cardiac and skeletal muscles genes, including muscle creatine kinase, α-skeletal actin, α-myosin heavy chain, myosin light chain 2, and α-cardiac actin. [15] [16] [17] [18] [19] Despite these studies, the ability of YY1 to activate cardiac gene expression, particularly during early cardiac development in mice, has not been examined. YY1, in cooperation with Gata4, activates the B-type natriuretic peptide promoter in vitro 20 and induces periostin enhancer expression in the cardiac outflow tract. 21 In a chick Nkx2.5 enhancer, YY1 was shown to modulate Smad-mediated Nkx2.5 expression. 22 Furthermore, YY1 binding to xenopus myosin light chain cardiac enhancer was necessary to induce full expression in transgenic embryos. 23 Although these studies provide suggestive evidence that YY1 may promote cardiac gene transcription during embryonic development, the requirement for YY1 to enhance cardiogenesis remains largely undefined. Furthermore, no study has addressed the role of YY1 during mammalian cardiac lineage commitment from multipotent mesodermal precursor cells.
In this study, we demonstrate that YY1 is required during early cardiac development. Genetic ablation of YY1 alleles in mesodermal cells resulted in early embryonic lethality. Using ESCs, we show that YY1 promotes cardiogenic differentiation. Detailed analysis of YY1-mediated transcriptional regulation at a cardiac-specific enhancer of Nkx2.5 revealed a direct requirement for YY1 DNA binding to activate gene expression. The in vivo binding of YY1 to this enhancer in embryonic-derived and ESC-derived CPCs was heart cellspecific, as demonstrated by chromatin immunoprecipitation (ChIP) and genome-wide sequencing analysis. Taken together, these results illustrate an essential role for YY1 to promote cardiogenic commitment by transcriptionally activating Nkx2.5 and other cardiac genes.
Methods
A detailed Methods section can be found in the Online Data Supplement.
Results

Screening for Regulators of Gene Expression in CPCs
During cardiac development, DNA-binding TFs that activate gene expression in CPCs are bound to the promoter/enhancer of genes enriched in CPCs. 24 We postulated that by examining bioinformatically the occurrence of overrepresented TF binding sites (TFBS) in the promoter regions of a set of overexpressed genes in CPCs, we might be able to identify key TFs that regulate the expression of these genes collectively ( Figure  1A ). We first identified a list of CPC-enriched genes by performing genome-wide transcriptional profiling of early CPCs at days 4 and 5 of ESC differentiation ( Figure 1B) . The global gene expression from each cell population was quantitated by microarray analysis ( Figure 1C ). After sample normalization and correction for multiple hypothesis testing, we identified a core set of 14 unique genes enriched in CPCs (false discovery rate <0.05; Figure 1C ). Gene ontology analysis confirmed that these genes (eg, Cnn1, Sema3C, Acta1, Acta2, Tnnc1, and Actc1, SM22, and Myl9) are associated with muscle contraction (P<0.0001) and muscle development (P<0.0001). Of note, cardiac TFs (including Nkx2.5) were excluded from this list because of their relatively lower level of expression.
To identify upstream TFs that may drive the expression of these 14 CPC-enriched genes, we performed a TFBS analysis on the sequences 5 kb upstream from the transcription start site of these genes using rVISTA, a computational tool that allows for identification of overrepresented TFBS. We found overrepresented TFBS for 44 TFs (Online Table I ). Notably, several of these TFs, including Smad, LEF1/TCF1, [25] [26] [27] Gli, Ets2, and Sp3, are involved in BMP, Wnt, Hedgehog, and other signaling pathways involved in normal cardiac development. [28] [29] [30] [31] [32] [33] We further refined this list by finding overrepresented TFBS in 5 regions (A, B, C, D, and E) of highly conserved DNA sequence between the mouse and human Nkx25 promoter ( Figure 1D ). Analysis of TFBS in these 5 regions resulted in 13 overrepresented TFBS (Online Table II ). From the 2 lists of candidate TFs (Online Tables I and II) , 3 factors-YY1, AP-2α, and myogenin-were present in both ( Figure 1E ). Immunostaining in the early developing heart tube showed that only YY1 has robust expression that coincides with the expression of Gata4 and Nkx2.5 ( Figure 1E ). Because cells from embryonic day 9.5 heart tubes have already matured beyond the CPC stage of development, the exact stage of development that YY1 plays a role in this process requires further investigation.
YY1 Binds Directly to an Nkx2.5 Cardiac Enhancer
To examine in detail the potential binding of YY1 to Nkx2.5 enhancer, we performed an electromobility shift assay using the 2.1-kb cardiac enhancer located within −9435 and −7353 bases upstream from the murine NKX25 transcriptional start site. 34 From 10 predicted YY1 binding sites (Figure 2A ), we found that YY1 binds specifically to sites 1, 2, 3, 6, and 9, but not sites 4, 5, 7, 8, and 10 ( Figure 2B ). Binding of site 1 to YY1 was further confirmed using a DNA supershift assay ( Figure  2C ). To corroborate these in vitro data with their binding to the Nkx2.5 cardiac enhancer in vivo, we performed ChIP and polymerase chain reaction (PCR) analysis using anti-YY1 antibodies on day 6 differentiated NK ESCs ( Figure 2D ), fluorescence-activated cell sorting-purified enhanced green fluorescent protein (eGFP) + CPCs and eGFP − cells from day 6 differentiated NK ESCs ( Figure 2E ), and from embryonic day 9.5 hearts and body ( Figure 2F ). As shown in Figure 2D through 2F, YY1 binds to the Nkx2.5 cardiac enhancer in cardiac cells but not in eGFP − and noncardiac cells from the embryonic day 9.5 embryo.
Identification of YY1 Target Genes in CPCs by Genome-Wide ChIP sequencing Analysis
Given the ability of YY1 to bind the Nkx2.5 cardiac enhancer both in vitro and in vivo, we postulated that YY1 may also bind to the promoter regions of other cardiac genes. We performed ChiP-sequencing (ChIP-seq) on YY1-bound chromatin in ESC-derived CPCs and identified ≈3700 unique binding peaks for YY1 ( Figure 3A) . Peak locations were analyzed with respect to Refseq gene models and transcription start site ( Figures 3B and 3C ). Gene ontology analysis of YY1-bound sites also identified genes belonging to the plasma membrane, cytoskeleton, intermediate filaments, and extracellular region ( Figure 3D ). Figure 3E ), as well as to the promoter/enhancer of cardiac sarcomeric genes, such as titin, tropomysin, myosin 18B, and Mkl2 (Online Figure IIA) . Analysis of overrepresented TFBS within the YY1-bound genomic regions revealed an enrichment of Gata4, AP-2, Foxc1, CEBPα, and others (Online Figure IIB) . Taken together, our in vitro studies and our genome-wide ChIP-seq analysis confirmed the binding of YY1 to the Nkx2.5 cardiac enhancer and to the promoter regions of several CPC-enriched genes. In addition, the binding of YY1 to the enhancer regions of other key cardiac TFs and sarcomeric proteins ( Figure 3E ; Online Figure IIC ) suggests that YY1 may be a critical transcriptional regulator of early cardiac development.
To examine the potential role of cooperative interactions between YY1 and other cardiac TFs to regulate gene expression, we focused on the co-occupancy of YY1 and Gata4 to their genome targets because a recent study showed that YY1 binding was enriched within Gata4-bound sites. 35 We extracted the data from this analysis performed on an HL1 cell line and cross-referenced with our YY1 ChIP-seq data from ESC-derived eGFP + cells to determine the candidate list of genes that are co-occupied by Gata4 and YY1. Interestingly, 195 genes were bound by both factors ( Figure  3G ). Gene ontology analysis clustered these genes within cell adhesion, cytoskeletal protein binding, cell migration, and phosphoproteins functional classes with a false discovery rate of <0.05 ( Figure 3H ). Although it should be emphasized that these 2 ChIP-seq data were from different cell sources and experimental contexts, the finding of a potential cooperative interaction between YY1 and Gata4 provided us with a compelling rationale for further exploring this interaction experimentally.
YY1 Regulates Nkx2.5 Cardiac Enhancer Activity in a Gata4-Dependent Manner
To examine the biological consequence of YY1 binding to the Nkx2.5 cardiac enhancer and the involvement of Gata4 in this process, we generated a series of luciferase reporter constructs ( Figure 4A ) to probe the requirement of YY1 and Gata4 DNA binding on the transcriptional activity of the Nkx2.5 enhancer. Using the H9C2 cardiomyocyte cell line, we first confirmed that overexpression of Gata4 induces a dose-dependent transcriptional activation of the full-length enhancer (wild-type [WT]; Figure 4B ), as previously described. 34 Without addition of exogenous YY1, we observed a considerable activation of the WT reporter by Gata4 alone, likely because of endogenous YY1 activity (data not shown). Interestingly, a majority of this transcriptional activation seems to reside within the first 330 bp containing a critical Gata4 binding site (GS1) ( Figure 4B ).
To identify whether direct DNA binding of YY1 is required for the transcriptional activation of the Nkx2.5 cardiac enhancer, we generated reporter constructs in which either all 5 YY1 (1, 2, 3, 6, and 9) binding sites (5BS) or 4 of 5 (2, 3, 6, and 9) binding sites (4BS) have been mutated. Remarkably, in the absence of YY1 DNA binding, the transcriptional activity of this enhancer is completely abolished ( Figure 4C ). The presence of only 1 binding site in the 4BS mutant is insufficient to rescue the transcriptional activation of this enhancer ( Figure 4C ). We further explored the relative requirement of each YY1 binding site to the transcriptional activation of the Nkx2.5 cardiac enhancer and found that 4 of these sites (1, 2, 3, and 9) are involved in Gata4-dependent transcriptional activation, whereas 1 site (6) may actually play a repressive role ( Figure 4D ). In support of this hypothesis, we found that the activity of the 5′ enhancer domain (1-330) is abolished when this repressive YY1 binding site (6) is present (Online Figure IIIA and IIIB) . Of note, the overexpression of YY1 does not lead to an increase in Gata4 expression in H9C2 cells (and vice versa), eliminating a potential confounder of our reporter assay results (Online Figure IIIC and IIID) .
To determine whether YY1 activity is dependent on DNA binding in the cardiac enhancer by Gata4, we generated mutant constructs in each of the 2 highly conserved Gata4 binding sites (GS1 and GS2; Figure 4A ) and found that modification of either of these sites renders the Nkx2.5 cardiac enhancer inactive ( Figure 4E ). Finally, we confirmed the requirement of YY1 binding to Nkx2.5 cardiac enhancer in vivo by generating transient transgenic mouse embryos from pronuclear injection of control and 5BS mutant Nkx2.5 cardiac enhancer/base promoter-LacZ constructs. We were able to generate a total of 26 collected embryos containing the WT construct and 25 embryos containing the 5BS mutant construct, which we confirmed by PCR. From the 26 embryos with the WT DNA construct, 6 showed LacZ + signal in the heart. In contrast, of the 25 embryos carrying the 5BS mutant construct, none exhibited LacZ + staining. A representative image of a LacZ stained heart is shown in Figure 4F .
To examine whether a direct physical interaction may exist between YY1 and Gata4 to mediate their synergistic effects, we performed a tandem YY1-Gata4 co-ChIP assay on day 6 in vitro differentiated NK ESCs ( Figure 4G ) and embryonic day e9.5 hearts ( Figure 4H ) and found that YY1 and Gata4 occupy nearby chromatin sites. Although it is possible that DNA-bound YY1 and Gata4 from 2 distant chromatin regions may be pulled down simultaneously in the presence of a third TF capable of binding to both proteins, we believe a direct YY1/Gata4 interaction is the most likely mechanism given our data showing that YY1 and Gata4 proteins interact with one another in a coimmunoprecipitation assay ( Figure 4I ). Further studies using ESC-derived eGFP + cells or heart cells will be needed to validate this H9C2 cell-based binding interaction. Taken together, these results demonstrate a cooperative interaction between YY1 and Gata4 to regulate the Nkx2.5 cardiac enhancer activity.
YY1 Loss-of-Function Results in Embryonic Lethality and the Absence of Cardiac Lineage Formation
Given the ability of YY1 to induce cardiac gene expression in CPCs, we postulate that YY1 may be required for proper cardiac lineage differentiation. We interbred floxed YY1 mice with Mesp1-Cre mice and observed no surviving embryo carrying both homozygous YY1 floxed alleles and the Mesp1-Cre allele from embryonic day 9.5 onward (Online Table IV) . At embryonic day 8.75 to 9.0, we found Mesp1-Cre + YY1 Flox/Flox (F/F) embryos that exhibit developmental arrest (3 of 3) with failure to undergo midline fusion ( Figure 5A ). These knockout embryos exhibit only 9 somites, whereas the WT and YY1 heterozygous embryos exhibit 11 somites ( Figure 5A ). By quantitative real-time PCR analysis of cells dissected from heart-forming regions of WT, heterozygous, and homozygous YY1 mutant embryos at day 7.5 after coitum, we found a marked reduction in the expression of Nkx2.5 and Isl-1 + in homozygous embryos, suggesting the loss of CPC formation ( Figure 5B ). We further confirmed this by performing an immunohistochemical analysis on embryonic 
YY1 Loss-of-Function Inhibits Cardiogenesis of NK ESCs
To gain access to cells that are most representative of differentiating cells in early embryos, we chose in vitro differentiated NK ESCs as a surrogate model. We first generated an YY1 inhibitor construct that contains the DNA-binding domain of YY1 that acts in a dominant-negative (DN) fashion. We then confirmed the ability of YY1-DN to silence the transcriptional activation of the Nkx2.5 cardiac enhancer using a luciferase assay in the H9C2 cell line ( Figure 6B ). We then further explored the effect of YY1-DN overexpression to inhibit cardiac lineage development in differentiating NK ESCs by generating doxycycline-inducible YY1-DN ESC lines and characterized multiple single-cell clonally derived cell lines (NK-YY1-DN ESC lines) for their ability to overexpress YY1-DN ( Figure  6C) . In one such line, doxycycline treatment resulted in ≈20-fold increase in YY1-DN expression and was further studied ( Figure 6D ). We then investigated the effect of YY1-DN overexpression on cardiac differentiation (as measured by the abundance of eGFP + cells) and found a ≈40% (1.4%±0.07% vs 0.85%±0.06%) reduction in the percentage of eGFP + cells with doxycycline treatment (Figure 6E and 6F) . This was corroborated by a marked reduction in expression of CPC markers, such as Nkx2.5, Isl-1, Gata4, and Tbx5 ( Figure 6G ).
YY1 Gain-of-Function Promotes Cardiogenesis of NK ESCs
Because our loss-of-function studies showed a requirement for YY1 in embryonic development and in cardiac differentiation of NK ESCs, we examined whether YY1 gain-of-function may lead to enhanced cardiogenesis. To address this, we generated a doxycycline-inducible YY1-overexpressing lentivirus using a previously described tet-on expression system (Online Figure VA) and infected the NK ESC line with this virus to generate multiple single-cell clonally derived inducible YY1 overexpressing NK ESC lines (NK-YY1) ( Figure 7A ). From reporters. E, Luciferase activity of full-length (WT) or Gata4 binding sites (GS1 or GS2) mutant reporters. F, WT and 5BS constructs were injected to generate embryonic day 9.5 transgenic embryos. Representative Xgal-stained embryos are shown. Sequential chromatin immunoprecipitation (co-ChIP) using antibodies against YY1 followed by antibodies against Gata4 on chromatin derived from day 6 NK embryonic stem cells (ESCs) (G) or embryonic day 10.5 embryonic hearts (H). I, Coimmunoprecipitation of endogenous YY1 and Gata4 using α-YY1 or α-IgG antibodies and nuclear extract from H9C2 cells. Bound proteins immunoblotted with antibodies against YY1 and Gata4. ***P<0.001; **P<0.05. EB indicates embryoid bodies; IB, immunoblot. the 32 lines examined, one of these was found to generate the highest increase in YY1 expression with doxycycline treatment (≈60-fold) and was used for further study ( Figure 7B) .
To assess the effects of YY1 overexpression on cardiac differentiation of ESCs, the NK-YY1 ESCs were differentiated in vitro for 6 or 10 days in the presence or absence of doxycycline induction ( Figure 7C ). We confirmed that doxycycline treatment led to a 60-fold and 22-fold increase in the expression of YY1 on days 6 and 10 of differentiation, respectively (Online Figure IVB) . As shown in Figure 7 , the percentage of early (day 6) and late (day 10) eGFP + cells increased in the presence of doxycycline treatment by ≈4-fold and 3-fold, respectively ( Figure 7D-7F) . In support of the increase in cardiac cell population after YY1 overexpression, the mRNA levels of several key CPC-associated TFs, such as Nkx2.5, Isl-1, Hand2, and Tbx5, were elevated by 2-fold to 10-fold at day 6 of differentiation ( Figure 7G ). The expression of vascular genes, such as vascular endothelial cadherin and smooth muscle actin-α, was increased as well ( Figure 7H ), supporting the role of YY1 to induce multipotent CPCs. 9 On day 10, the increase in the percentage of cardiomyocytes with YY1 overexpression was corroborated by a 10-fold to 50-fold increase in cardiac TF expression (Online Figure VC) and a 20-fold to 30-fold increase in the expression of sarcomeric genes, such as Mlc2v and cTnT ( Figure 7I ). Although the increase in eGFP + cell percentage (3-fold to 4-fold) by flow cytometry was significantly less than the increase in gene expression (10-fold to 50-fold), we believe this may be because of the differences in the method of quantification (flow cytometry vs quantitative PCR) and the transcriptional activity of YY1 at these genes.
YY1 Induces Mesodermal Stage Precursors Into CPCs
To determine precisely the developmental window that YY1 acts to promote cardiac differentiation, we induced the overexpression of YY1 from either days 0 to 3 (ie, analogous to pregastrulation stage cells) or 3 to 6 (ie, analogous to germ layer stage cells) of in vitro differentiation of NK-YY1 ES cells ( Figure  8A ). When compared with untreated cells as control, doxycycline treatment from days 3 to 6 led to a >3-fold increase in the percentage of eGFP + cells at day 6 of differentiation ( Figure  8B and 8C) . Interestingly, treatment of doxycycline from days 0 to 3 of differentiation resulted in no increase in eGFP + cells ( Figure 8C ). The overexpression of YY1 from day 3 to 6 also induced a dramatic increase in the transcript levels of Nkx2.5 and Tbx5 (>150-fold and 40-fold, respectively) ( Figure 8D ) without a parallel increase in the expression of endoderm, ectoderm, and some noncardiac mesoderm genes (Online Figure  VI) . These findings support a specific role for YY1 to enhance cardiogenic commitment from mesodermal precursor cells.
Discussion
To gain insights into early cardiac development, we used a combination of expression and bioinformatic analysis that led to the identification of YY1 as a novel candidate gene in early cardiogenesis. We confirmed the in vivo binding of YY1 to an Nkx2.5 cardiac enhancer in both ESC and embryoderived cardiac cells by ChIP. We also found that YY1, in cooperation with Gata4, drives the expression of the Nkx2.5 cardiac enhancer and may physically associate with Gata4. Conditional YY1 deletion in the developing mouse mesoderm resulted in early embryonic lethality and failure of midline fusion. In ESC-based assays, the loss-of-function of YY1 resulted in decreased cardiac lineage cells, whereas YY1 gainof-function enhanced the generation of cardiac cells. Taken together, these results demonstrate a requirement for YY1 to promote the transition of mesodermal precursors to CPCs via direct transcriptional regulation of cardiac genes.
Identification of Novel TFs Involved in Early Cardiogenesis
Although the transcription network driving cardiac gene expression during embryonic development has been intensely studied, [36] [37] [38] [39] [40] there has been relatively few efforts focusing on the developmental transition from mesodermal precursors to committed CPCs. During gastrulation, mesodermal precursors that are destined for a cardiovascular fate express Mesp1/2. [41] [42] [43] Mesp1 overexpression enhances the commitment of multipotent mesodermal cells into CPCs, inducing the expression of key cardiac TFs, such as Nkx2.5, Isl-1, and Tbx5. 44, 45 Here, we identified YY1 as a regulator of cardiogenesis by its regulation of CPC gene expression. We also found that other TFs, such as AP-2α, Ets2, and Gli, may play important roles in early cardiac development as well. In support of this, signaling by sonic hedgehog has been shown to regulate the number of myocardial progenitor cells in the arterial pole during zebrafish heart development. 46, 47 The formation of cardiac precursors in ascidian Ciona intestinalis requires activation of Ci-Ets2. 48 Further investigation into the biological requirement of these and other factors during mesodermal to CPC transition in mice will be informative.
Regulation of NKX2.5 Expression by YY
We performed an in-depth analysis of the regulation of Nkx2.5 expression by YY1 because Nkx2.5 is one of the earliest genes expressed in heart-forming precursors and plays an essential role in cardiac development. 49, 50 We found that YY1 functions cooperatively with Gata4 on nearby chromatin. Recent genome-wide target analysis in the HL1 cell line by ChIP-seq for these cardiac TFs has found co-occupancy of SRF, Tbx5, and Gata4 along with p300 within the YY1 binding region on the Nkx2.5 enhancer. 35 This implies that YY1 is able to regulate cardiac-specific gene expression by its association with other cardiac TFs. In support of this, we identified an overrepresentation of binding sites for Gata4, CEBPα, and Foxc1 in YY1 ChIP-seq target regions ( Figure 3D ). These genes are all known to play important roles during early cardiac development.
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Regulation of Other Cardiac Gene Expression by YY1
Our genome-wide analysis also has found many other cardiac genes (eg, Tbx3, Tbx5, Pitx2, and Mef2c, etc) that are potentially regulated by YY1. Of interest, Tbx3 is expressed in the outflow tract, the atrioventricular canal, and the central conduction system, and is required for normal alignment of the outflow tract and for normal ventricular septation. 55 Pitx2 plays a critical role in regulating left-right asymmetry during heart development and is a direct downstream effector of sonic hedgehog signaling. 47 The occupancy of YY1 in their promoter/enhancer regions during the mesodermal stage of 
Context-Dependent Regulation of Cardiac Transcriptional Program by YY1
A surprising aspect of our studies here is the role of YY1 to transcriptionally activate genes in early cardiac development despite the role of YY1 as a transcriptional repressor of sarcomeric genes. [15] [16] [17] [18] [19] 56 Although a few in vivo studies have found correlation between increased YY1 expression and decreased sarcomeric gene expression during pathological cardiac hypertrophy, 19 most of the existing data are based on in vitro luciferase assays. In the adult heart, the expression of YY1 is attenuated but increases in response to pathological hypertrophy. The repressive function of YY1 in this context seems to involve the recruitment of HDAC5 to sarcomeric gene loci. In support of a contextdependent role of YY1 in cardiac lineage, we found that the ability of YY1 to induce Gata4-dependent Nkx2.5 cardiac enhancer expression is abolished in differentiated H9C2 cells (Gregoire and Wu, unpublished data).
Conclusion
In summary, we describe here an essential and unexpected role of YY1 in early cardiac development. Our in vivo data to genetically ablation YY1 alleles and our transcriptional reporter assays in vitro as well as our ESC-based gain-of-function and loss-of-function studies all point to a requirement for YY1 to regulate early cardiac development. Taken together, these results demonstrate a critical role for YY1 to regulate mesodermal cardiac commitment by regulating cardiac gene expression. + cells present is labeled. C, Quantification of eGFP + cells present at day 6 of differentiation after doxycycline treatment during days 0 to 3 (0-3) or days 3 to 6 (3-6) of differentiation. D, Quantitative polymerase chain reaction analysis of Nkx2.5 and Tbx5 expression at day 6 of differentiation in cells treated with doxycycline from days 0 to 3 or 3 to 6. ***P<0.001.
